{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:48:27Z","timestamp":1782805707302,"version":"3.54.5"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>XT1061 is a newly developed oral small-molecule agent designed to promote the assembly of empty capsids devoid of pregenomic RNA, representing a potential therapeutic approach for chronic hepatitis B (CHB). This first-in-human trial aimed to assess the pharmacokinetic profile and tolerability of single ascending doses and multiple doses of XT1061 in healthy Chinese individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Phase Ia clinical study consisted of two components: a double-blind, randomized, placebo-controlled, single-ascending-dose assessment conducted under fasting conditions across dose levels ranging from 12.5\u00a0mg to 600\u00a0mg\u2014including a food-effect evaluation at 62.5\u00a0mg\u2014followed by a multiple-dose regimen at 250\u00a0mg administered under fasting conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>XT1061 demonstrated good tolerability in healthy Chinese participants, with no notable difference in the incidence of adverse events between the XT1061 and placebo groups. Following administration, the median time to peak concentration ranged from 1.0 to 2.5\u00a0h, while the mean elimination half-life varied between 2.864 and 11.478\u00a0h. Systemic exposure exhibited an approximately dose-proportional increase. Steady-state concentrations were achieved within approximately 2\u00a0days of repeated dosing, with mean accumulation indices ranging from 1.043 to 1.333. Additionally, concomitant food intake reduced the peak plasma concentration by approximately 50%, although it had no significant impact on total systemic exposure, as measured by the area under the curve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings indicate that XT1061 possesses a favorable safety profile and predictable pharmacokinetics, providing a solid foundation for advancing into further clinical investigations to evaluate its efficacy and safety in patients with CHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:ext-link>http:\/\/www.chinadrugtrials.org.cn\/index.html<\/jats:ext-link>\n                      ], identifier [CTR20232071].\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1860210","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:36:09Z","timestamp":1782804969000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["First-in-human study on the pharmacokinetics, safety, and tolerability of single escalating doses and multiple doses of XT1061, a novel core protein allosteric modulator, in healthy Chinese subjects"],"prefix":"10.3389","volume":"17","author":[{"given":"Qingmei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pediatric Nephrology, Children\u2019s Medical Center, The First Hospital of Jilin University","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center, The First Hospital of Jilin University","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center, The First Hospital of Jilin University","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhen","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center, The First Hospital of Jilin University","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center, The First Hospital of Jilin University","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xu","sequence":"additional","affiliation":[{"name":"Xi\u2019an Xintong Pharmaceutical Research Co., Ltd.","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Xi\u2019an Xintong Pharmaceutical Research Co., Ltd.","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangkai","family":"Sun","sequence":"additional","affiliation":[{"name":"Xi\u2019an Xintong Pharmaceutical Research Co., Ltd.","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchi","family":"Li","sequence":"additional","affiliation":[{"name":"School of Nursing, Xi\u2019an Jiaotong University Health Science Center","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Ding","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center, The First Hospital of Jilin University","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hepatology, The First Hospital of Jilin University","place":["Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12879-023-08110-5","article-title":"Seroprevalence of hepatitis B virus surface antigen (HBsAg) in Egypt (2000-2022): a systematic review with meta-analysis","volume":"23","author":"Azzam","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"103647","DOI":"10.1016\/j.esmoop.2024.103647","article-title":"Pan-asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/v14020434","article-title":"Current trend in antiviral therapy for chronic hepatitis B","volume":"14","author":"Chien","year":"2022","journal-title":"Viruses"},{"key":"B4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.antiviral.2018.07.011","article-title":"Novel non-heteroarylpyrimidine (HAP) capsid assembly modifiers have a different mode of action from HAPs in vitro","volume":"158","author":"Corcuera","year":"2018","journal-title":"Antivir. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1056\/nejmra2211764","article-title":"New approaches to chronic hepatitis B","volume":"388","author":"Dusheiko","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12916-023-02814-w","article-title":"Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial","volume":"21","author":"Jia","year":"2023","journal-title":"BMC Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.gastha.2023.01.001","article-title":"Safety, tolerability, and pharmacokinetics of a novel human hepatitis B virus capsid assembly modulator canocapavir: a randomized first-in-human study","volume":"2","author":"Jiang","year":"2023","journal-title":"Gastro Hep Adv."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1007\/s11095-008-9645-9","article-title":"Bioavailability and bioequivalence: focus on physiological factors and variability","volume":"25","author":"Karalis","year":"2008","journal-title":"Pharm. Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1136\/gutjnl-2023-330691","article-title":"Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people","volume":"72","author":"Liu","year":"2023","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/14728222.2017.1397134","article-title":"Hepatitis B core protein as a therapeutic target","volume":"21","author":"Mak","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1186\/s12889-022-14618-3","article-title":"A nationwide cross-sectional review of in-hospital hepatitis B virus testing and disease burden estimation in Ghana, 2016 - 2021","volume":"22","author":"Nartey","year":"2022","journal-title":"BMC Public Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1434816","DOI":"10.3389\/fpubh.2024.1434816","article-title":"Seroprevalence of hepatitis B virus surface antigen among African blood donors: a systematic review and meta-analysis","volume":"12","author":"Quintas","year":"2024","journal-title":"Front. Public Health"},{"key":"B15","doi-asserted-by":"publisher","first-page":"104557","DOI":"10.1016\/j.antiviral.2019.104557","article-title":"BAY 41-4109-mediated aggregation of assembled and misassembled HBV capsids in cells revealed by electron microscopy","volume":"169","author":"Rat","year":"2019","journal-title":"Antivir. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12985-024-02584-8","article-title":"Safety, pharmacokinetics, and antiviral efficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized, placebo-controlled design","volume":"21","author":"Wu","year":"2024","journal-title":"Virol. J."},{"key":"B17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40261-025-01477-0","article-title":"Emerging trends and future directions in the development of anti-hepatitis B therapies: a horizon scanning review","volume":"45","author":"Yao","year":"2025","journal-title":"Clin. Drug Investig."},{"key":"B18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S2468-1253(19)30346-2","article-title":"Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial","volume":"5","author":"Yuen","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S2468-1253(21)00176-X","article-title":"Safety, pharmacokinetics, and antiviral activity of RO7049389, a core protein allosteric modulator, in patients with chronic hepatitis B virus infection: a multicentre, randomised, placebo-controlled, phase 1 trial","volume":"6","author":"Yuen","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fphar.2018.00849","article-title":"Association of variability and pharmacogenomics with bioequivalence of gefitinib in healthy Male subjects","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/cid\/ciaa961","article-title":"Antiviral activity and pharmacokinetics of the hepatitis B virus (HBV) capsid assembly modulator GLS4 in patients with chronic HBV infection","volume":"73","author":"Zhang","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"873588","DOI":"10.3389\/fphar.2022.873588","article-title":"First-in-human study on pharmacokinetics, safety, and tolerability of single and multiple escalating doses of hepenofovir, a novel hepatic targeting prodrug of tenofovir in healthy Chinese subjects","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"42374","DOI":"10.1038\/srep42374","article-title":"Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA) inhibit hepatitis B virus replication by different molecular mechanisms","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","article-title":"JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection","volume":"159","author":"Zoulim","year":"2020","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41575-022-00700-z","article-title":"Nomenclature of HBV core protein-targeting antivirals","volume":"19","author":"Zoulim","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1860210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:36:09Z","timestamp":1782804969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1860210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":25,"alternative-id":["10.3389\/fphar.2026.1860210"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1860210","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"1860210"}}